Literature DB >> 18308332

Upregulation of myocardial 11S-activated proteasome in experimental hyperglycemia.

Saul R Powell1, Samson Mathews Samuel, Ping Wang, Andras Divald, Mahesh Thirunavukkarasu, Srikanth Koneru, Xuejun Wang, Nilanjana Maulik.   

Abstract

This study examined the hypothesis that the ubiquitin proteasome system (UPS) degrades proteins damaged by exposure to hyperglycemia. Experimental hyperglycemia was induced in male rats by treatment with streptozotocin. After 30 days, echocardiography confirmed the presence of cardiomyopathy as ejection fraction, fractional shortening, and diastolic function (E/A ratio) were decreased, and chamber diameter was increased in hyperglycemic animals. Proteasome non-ATP-dependent chymotryptic activity was increased over 2-fold in hyperglycemic hearts, but the ATP-dependent activity was decreased and levels of ubiquitinated proteins were increased. Protein levels of the PA28alpha of the 11S-activator ring were increased by 128% and the PA28beta subunit increased by 58% in the hyperglycemic hearts. The alpha3 subunit of the 20S-proteasome was increased by 82% while the catalytic beta5 subunit was increased by 68% in hyperglycemic hearts. Protein oxidation as indicated by protein carbonyls was significantly higher in hyperglycemic hearts. These studies support the conclusion that the UPS becomes dysfunctional during long term hyperglycemia. However, 11S-activated proteasome was increased suggesting a response to oxidative protein damage and a potential role for this form of the proteasome in a cardiac pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308332     DOI: 10.1016/j.yjmcc.2007.12.009

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  26 in total

Review 1.  Post-translational modification of cardiac proteasomes: functional delineation enabled by proteomics.

Authors:  Sarah B Scruggs; Nobel C Zong; Ding Wang; Enrico Stefani; Peipei Ping
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-20       Impact factor: 4.733

Review 2.  The ubiquitin-proteasome system and cardiovascular disease.

Authors:  Saul R Powell; Joerg Herrmann; Amir Lerman; Cam Patterson; Xuejun Wang
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

3.  Proteomic analysis reveals perturbed energy metabolism and elevated oxidative stress in hearts of rats with inborn low aerobic capacity.

Authors:  Jatin G Burniston; Jenna Kenyani; Jonathan M Wastling; Charles F Burant; Nathan R Qi; Lauren G Koch; Steven L Britton
Journal:  Proteomics       Date:  2011-08       Impact factor: 3.984

4.  Enhancement of proteasome function by PA28α overexpression protects against oxidative stress.

Authors:  Jie Li; Saul R Powell; Xuejun Wang
Journal:  FASEB J       Date:  2010-11-23       Impact factor: 5.191

Review 5.  Proteasome inhibitors and cardiac cell growth.

Authors:  Nadia Hedhli; Christophe Depre
Journal:  Cardiovasc Res       Date:  2009-07-03       Impact factor: 10.787

Review 6.  Protein quality control and degradation in cardiomyocytes.

Authors:  Xuejun Wang; Huabo Su; Mark J Ranek
Journal:  J Mol Cell Cardiol       Date:  2008-05-20       Impact factor: 5.000

Review 7.  The ubiquitin-proteasome system in myocardial ischaemia and preconditioning.

Authors:  Saul R Powell; Andras Divald
Journal:  Cardiovasc Res       Date:  2009-09-30       Impact factor: 10.787

Review 8.  Role of various proteases in cardiac remodeling and progression of heart failure.

Authors:  Alison L Müller; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

Review 9.  Proteasome functional insufficiency in cardiac pathogenesis.

Authors:  Xuejun Wang; Jie Li; Hanqiao Zheng; Huabo Su; Saul R Powell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-23       Impact factor: 4.733

Review 10.  The ubiquitin proteasome system and myocardial ischemia.

Authors:  Justine Calise; Saul R Powell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-07       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.